We develop, manufacture, and deliver medical countermeasures that address public health threats.
ACAM2000®
(Smallpox and Mpox (Vaccinia) Vaccine, Live)
ANTHRASIL®
[Anthrax Immune Globulin Intravenous (Human)]
BAT®
[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]
BioThrax®
(Anthrax Vaccine Adsorbed)
- US Prescribing Information
- Information Summary of Product Characteristics (Common – English version; Approved in DE, IT, FR, NL, PL, UK/NI)
- Information Package Information Leaflet (Common – English version; Approved in DE, IT, FR, NL, PL, UK/NI)
- Canadian Product Monograph (English)
- Canadian Product Monograph (French)
CYFENDUS®
(Anthrax Vaccine Adsorbed, Adjuvanted)
Ebanga™*
(ansuvimab-zykl)
raxibacumab injection
A fully human monoclonal antibody
Trobigard® Auto-injector**
(atropine sulfate, obidoxime chloride auto-injector)
VIGIV®
[Vaccinia Immune Globulin Intravenous (Human)]
*EbangaTM is a trademark of RIDGEBACK BIOTHERAPEUTICS L.P.
**On April 2, 2024, Emergent submitted its revocation of the Market Authorization for the Trobigard Auto-Injector to the Belgium Federal Agency for Medicines and Health Products (FAMHP). The FAHMP subsequently acknowledged and confirmed the revocation date as being April 2, 2024. As such, Emergent has discontinued production of Trobigard, and the product is no longer available; however, we remain committed to public health preparedness and will continue to work with allied governments to protect soldiers and civilians across the globe.